Capital Advisors Ltd. LLC Buys 358 Shares of Zoetis Inc. (NYSE:ZTS)

Capital Advisors Ltd. LLC boosted its stake in Zoetis Inc. (NYSE:ZTSGet Rating) by 108.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 688 shares of the company’s stock after acquiring an additional 358 shares during the period. Capital Advisors Ltd. LLC’s holdings in Zoetis were worth $130,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Horizon Investments LLC boosted its holdings in shares of Zoetis by 5.5% during the 4th quarter. Horizon Investments LLC now owns 9,113 shares of the company’s stock valued at $2,220,000 after buying an additional 477 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Zoetis by 6.3% during the 1st quarter. Revolve Wealth Partners LLC now owns 1,153 shares of the company’s stock valued at $217,000 after buying an additional 68 shares in the last quarter. Mn Services Vermogensbeheer B.V. boosted its holdings in shares of Zoetis by 1.9% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 362,603 shares of the company’s stock valued at $88,486,000 after buying an additional 6,800 shares in the last quarter. Elk River Wealth Management LLC boosted its holdings in shares of Zoetis by 22.6% during the 1st quarter. Elk River Wealth Management LLC now owns 30,672 shares of the company’s stock valued at $5,784,000 after buying an additional 5,651 shares in the last quarter. Finally, Freedom Day Solutions LLC boosted its holdings in shares of Zoetis by 0.9% during the 4th quarter. Freedom Day Solutions LLC now owns 10,258 shares of the company’s stock valued at $2,503,000 after buying an additional 92 shares in the last quarter. Institutional investors own 90.73% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research reports. The Goldman Sachs Group dropped their target price on shares of Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a report on Thursday, July 21st. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. Piper Sandler assumed coverage on Zoetis in a research report on Monday, July 11th. They issued an “overweight” rating and a $205.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Friday. Finally, Stifel Nicolaus lowered their price target on Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, June 24th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Zoetis has an average rating of “Moderate Buy” and a consensus target price of $224.88.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $174.61 on Friday. Zoetis Inc. has a fifty-two week low of $154.18 and a fifty-two week high of $249.27. The business has a 50-day simple moving average of $171.80 and a two-hundred day simple moving average of $181.35. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.58 and a current ratio of 2.25. The firm has a market cap of $82.18 billion, a price-to-earnings ratio of 39.59, a price-to-earnings-growth ratio of 2.96 and a beta of 0.73.

Zoetis (NYSE:ZTSGet Rating) last issued its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). Zoetis had a return on equity of 48.90% and a net margin of 26.14%. The business had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same period last year, the firm posted $1.19 EPS. Zoetis’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, analysts expect that Zoetis Inc. will post 5.03 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Thursday, July 21st will be given a dividend of $0.325 per share. This represents a $1.30 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Wednesday, July 20th. Zoetis’s payout ratio is currently 29.48%.

Insider Activity

In other news, Director Willie M. Reed sold 1,855 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $162.31, for a total transaction of $301,085.05. Following the completion of the sale, the director now owns 6,782 shares of the company’s stock, valued at approximately $1,100,786.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Roxanne Lagano sold 4,334 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $175.00, for a total transaction of $758,450.00. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,145,225. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,855 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $162.31, for a total value of $301,085.05. Following the transaction, the director now owns 6,782 shares of the company’s stock, valued at $1,100,786.42. The disclosure for this sale can be found here. Insiders sold 18,356 shares of company stock valued at $3,250,158 in the last quarter. 0.12% of the stock is currently owned by insiders.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Stories

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.